A new financial disclosure shows a roughly $50,000–$100,000 purchase of Amgen shares tied to Rep. Ro Khanna, adding the California Democrat to the long list of lawmakers who have traded one of the biotechnology sector’s biggest companies.
The transaction, dated Feb. 24, 2026, involved shares of AMGN, the Nasdaq‑listed biotech giant with a market capitalization of about $197.4 billion. The purchase was reported as owned by “DC,” indicating a dependent child account in the disclosure.
Based on the reported range, the investment is estimated at roughly $75,000.
Details from the disclosure
- Lawmaker: Rep. Ro Khanna (D‑Calif.)
- Company: Amgen Inc. (NASDAQ: AMGN)
- Transaction type: Buy
- Reported range: $50,000–$100,000
- Estimated value: about $75,000
- Date: Feb. 24, 2026
- Owner: Dependent child (DC)
Members of Congress are required under the STOCK Act to disclose securities transactions within 45 days, a rule designed to increase transparency around lawmakers’ financial activity.
A biotech heavyweight closely watched by investors
Amgen remains one of the most established biotechnology companies in the United States. The firm built its reputation on blockbuster biologic medicines including Enbrel, Prolia and Otezla, which continue to generate durable revenue years after launch.
Investors track the company for several reasons: steady cash flows from legacy therapies, a growing biosimilars business, and a late‑stage drug pipeline aimed at cancer, cardiovascular disease and autoimmune conditions. The company is also active in biotechnology dealmaking, a factor that often influences sector valuations.
As of recent trading, Amgen shares hover around $366.21. That price level places the company among the largest pure‑play biotech firms globally.
Amgen’s popularity on Capitol Hill
Khanna is far from alone in owning or trading the biotech stock. According to congressional financial disclosures, 55 lawmakers have reported transactions involving Amgen in recent years.
The company’s size, consistent profitability and large dividend have historically made it a common holding among diversified portfolios, including those reported by members of Congress.
Khanna himself has been an active filer of financial disclosures over time, with databases tracking 19,625 career trades connected to accounts listed in his filings.
While Khanna serves on several high‑profile panels—including the House Armed Services Committee and the House Oversight and Government Reform Committee—none of his current committee assignments directly oversee biotechnology drug approvals or pharmaceutical regulation.
Still, congressional trading disclosures often attract scrutiny as policymakers debate whether lawmakers should be allowed to own individual stocks at all. Several bipartisan proposals aimed at restricting or banning congressional stock trading have circulated in recent sessions.
For readers tracking market activity tied to elected officials, this purchase adds to the stream of latest congressional trades reported across Capitol Hill.